Drugs / GX-G3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01951027 | Sep 2013 → Jul 2014 | — | Genexine, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GX-G3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01951027 ↗ |
| Known as | GX-G3(G-CSF-hyFc) | “GX-G3(G-CSF-hyFc)” NCT01951027 ↗ |
| Route | Subcutaneous | “Single SC injection” NCT01951027 ↗ |